| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Applied Therapeutics stock falls after FDA feedback prompts another Type C meeting to discuss the Phase 3 plan for its CMT-SORD...
Applied Therapeutics (NASDAQ:APLT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of ...
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here...